Parker Waichman LLP

Vytorin Sales Dip Means Layoffs at Schering-Plough

The Vytorin controversy is still hurting sales of the once-blockbuster cholesterol drug, with prescriptions down one-third this year.  To stem the bleeding, Schering-Plough, which markets Vytorin with Merck & Co., has announced that it will be eliminating 20 percent of its sales force.  The elimination of 1000 sales reps is part of companywide reductions announced […]

The <"https://www.yourlawyer.com/topics/overview/vytorin">Vytorin controversy is still hurting sales of the once-blockbuster cholesterol drug, with prescriptions down one-third this year.  To stem the bleeding, Schering-Plough, which markets Vytorin with Merck & Co., has announced that it will be eliminating 20 percent of its sales force.  The elimination of 1000 sales reps is part of companywide reductions announced earlier this year aimed at cutting $1.5 billion in costs by 2012.

Vytorin’s troubles started in January, with the release of the long-delayed ENHANCE study.  That study showed that Vytorin was ineffective in preventing clogged arteries, and might actually increase plaque in some users. When ENHANCE was vetted during the annual meeting of the American College of Cardiology in March, doctors there recommended that it be used only as a last resort. “Our strongest recommendation is that people need to go back to statins,” said panel member Dr. Harlan Krumhotz.

While the ENHANCE results caused a stir, even more controversy surrounded the way it was handled.  Merck and Schering-Plough delayed releasing ENHANCE for more than a year – something critics have likened to fraud.  In addition, the companies attempted to change the study’s endpoint – the main result it was meant to measure – after it was completed.  It is generally accepted that for a clinical trial to be effective, a study’s endpoint must be set at its beginning and remain unchanged. In December 2007, in response to the ENHANCE delays and the attempt by Merck and Schering-Plough to change the endpoint, Congress initiated an investigation of the ENHANCE study. The companies dropped their attempt to change the ENHANCE endpoint shortly thereafter.

Vytorin took another hit over the summer, when the SEAS study was released.  SEAS was designed to see if the drug helped people with aortic stenosis avoid heart attacks.  Not only did SEAS show that Vytorin offered no additional heart attack prevention, but Vytorin patients enrolled in the study had higher rates of cancer than those taking a placebo. In the trial, 102 patients taking Vytorin developed cancer, compared with 67 taking the placebo. Of those, 39 people taking Vytorin died from their cancer, compared with 23 taking placebo. Researchers conducting the study said that while those numbers don’t prove a definitive cancer link, they were “statistically significant”, meaning the odds were less than 5 percent that they were the result of chance.

At the time it released SEAS, Merck and Schering-Plough also released an analysis of ongoing Vytorin trials that they said showed the SEAS cancer results to be an anomaly.  But not everyone is convinced, and Congress recently expanded its Vytorin investigation to include the handling of SEAS.

At its peak, Vytorin posted sales of $5 billion.  With its sales now in the tank, Schering-Plough had to find ways to reduce costs.  Schering-Plough Chief Executive Officer Fred Hassan said in April that the company would trim 10 percent off its 2007 costs to offset the decline.  In addition to reducing the sales force, Schering-Plough is firing workers after acquiring Organon Biosciences NV.

“The company emphasized that it highly values the work of its sales professionals, and so the decision to eliminate positions was difficult,” Schering-Plough said in a statement announcing the cuts.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Positive: Professionalism Always kept me informed in a timely manner
Donald Dodson
2 years ago
5 Star Reviews 150
Edward Mooney
6 years ago
5 Star Reviews 150
My husband lost his parents within 2 years. His father most recently and we are distraught over his care prior to passing. We decided to call Parker Waichman, and were greeted by Joanna. We sat and explained our story, and literally felt like we were sitting with family. Joanna went out of her way to make sure we understood every single detail, and were comfortable with our choices. Lawyers can be intimidating, but we never once felt that way. We are very comfortable with our choice to use them and would recommend anyone to use their services. (Joanna even went out of her way to hand deliver the most delicious olive oil, not sold in the U.S to our home!!)
Diane Terracciano
3 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038